Increase in myocardial digoxin content associated with circulatory volume overload in the dog

Acute myocardial uptake of digoxin in humans: correlation with hemodynamic and electrocardiographic effects

Acute myocardial uptake of digoxin was measured at a constant paced heart rate (75 beats/min) for 30 min after an intravenous bolus injection of 500 micrograms of digoxin in 14 patients with ischemic heart disease. Myocardial digoxin content, determined by serial measurement of aortocoronary sinus digoxin concentration gradients and coronary sinus blood flow, was expressed relative to coronary sinus blood flow at rest and correlated with simultaneous hemodynamic and electrocardiographic changes. Myocardial digoxin uptake was extensive (4.1 +/- 0.7% of total injected dose at 30 min) and prolonged, with rapid initial uptake (75.3 +/- 6.6% of maximum at 3 min), followed by a variable phase of slower accumulation. Peak left ventricular positive first derivative of left ventricular pressure (dP/dt) increased progressively (p less than 0.01), with a similar time course to that of myocardial digoxin accumulation; maximal change was 18.5 +/- 4.7% at 27 min. The ratio of inotropic effect to myocardial digoxin content did not vary significantly over the period of the experiment. However, peak inotropic effects in individual patients were not significantly related to peak myocardial digoxin content. The spontaneous PR interval increased transiently, with a peak increase of 5.9 +/- 1.8% (p less than 0.05) 12 min after digoxin administration. It is concluded that after intravenous bolus administration, 1) peak effects of digoxin on atrioventricular (AV) conduction occur early, whereas positive inotropic effects increase progressively for greater than or equal to 27 min; and 2) digoxin accumulation in the human myocardium is prolonged and is a determinant of inotropic effects, but not of prolongation of AV node conduction.

The influence of heart rate on digoxin-induced inhibition of myocardial Na+-K+-ATPase activity in the dog

1. Groups of sedated dogs were studied at spontaneous heart rates (HR), 55-100/min, or at paced HR 200/min, with or without intravenous digoxin administration. After 60 min, active rubidium uptake (86 Rb+) of ventricular samples was determined in vitro. 2. Untreated fast and slow HR groups had similar uptakes. Following digoxin, 0.08 mg/kg, uptake was less at fast than slow HR (63.8, s.e.m. = 4.5 v. 87.5, s.e.m. = 5.0 pmol/mg LV/15 min, P less than 0.01). After 0.125 mg/kg, values were again lower in the fast HR group in which five of seven developed ventricular tachycardia. 3. Heart rate does not alter in vitro activity of myocardial Na+-K+-ATPase but does influence inhibition of the enzyme resulting from digoxin administration.

Myocardial ouabain content and susceptibility to ouabain cardiotoxicity associated with circulatory volume overload in the dog

The influence of circulatory volume overload on the myocardial uptake of ouabain and on cardiotoxicity was studied in the unanaesthetised dog with aorto-caval fistula. One hour after tritiated ouabain (0-02 mg/kg IV) both ventricles and atria contained more ouabain than did those of normal dogs (left ventricle (LV), 166+/-23 (SD) ng/g vs. 97+/-19 ng/g, P less than 0-001) while concentrations in skeletal muscle, liver, kidney and plasma were not different in the two groups. In other experiments ouabain was infused to cardiotoxicity (7-5 microgram/kg followed by 3 microgram/kg/min). Cardiotoxicity occurred earlier in dogs with fistula than in normals (16-5+/-2-7 min vs. 24-1+/-2-4 min, P less than 0-001). Ouabain concentrations in myocardium were not different (LV, 434+/-58 ng/g, vs. 442+/-42 ng/g) while concentrations in liver and kidney were less in those with fistula (181+/-35 ng/g vs. 278+/-69 ng/g, P less than 0-001; 1422+/-189 ng/g vs. 2747+/-479 ng/g, P less than 0-001). Average content of skeletal muscle was also less, in proportion to administered dose. The increment in myicardial ouabain content associated with aorto-caval fistula appears to be physiologically active and hence is presumably specifically bound to the digitalis receptor. The observations in this model suggest the possibility of augmented cardiac glycoside uptake in some clinical cardiac diseases.